Cargando…
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Despite the promising advances in novel cancer therapy such as immune checkpoint inhibitors (ICIs), limitations including therapeutic resistance and toxicity remain. In recent years, the relationship between gut microbiota and cancer has been extensively studied. Accumulating evidence reveals the ro...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185832/ https://www.ncbi.nlm.nih.gov/pubmed/35277453 http://dx.doi.org/10.1136/gutjnl-2021-326264 |